A report designed to help advocates understand results of the 2010 CAPRISA 004 trial and how they related to the research agenda for ARV-based prevention strategies.
A Cascade of Hope and Questions: Anticipating results of ARV-based HIV prevention trials
Understanding the Results of CAPRISA 004
A 2010 document discussing the results of the CAPRISA 004 microbicide gel trial. It explores the implications of the data and outlines the next steps in evaluating tenofovir gel.
From Research to Reality: Investing in HIV prevention research in a challenging landscape
Summary of findings from report on 2012 investment and funding trends in HIV prevention research and development (R&D).
Next steps for PrEP: Getting a proven prevention option to the people who need it
An article from the June 2013 edition of the GMHC newsletter discussing issues of PrEP introduction worldwide, reviewing efficacy trial results and current status of regulatory approval of Truvada as PrEP and rollout efforts.
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
Viral Load Testing Delivers Systemic Benefits from the Individual to the Institution
This graphic from AVAC Report 2013 highlights the benefits of routine viral load testing for both individuals and institutions. Expanding access to viral load testing is a key step toward achieving virologic suppression.
The Global HIV Treatment U=U Gap: Existing people on ART versus people eligible under past and current WHO guidelines
This year WHO released eagerly anticipated comprehensive antiretroviral Treatment U=U (ART) guidelines addressing how to optimize ART for both Treatment U=U and prevention. The guidance recommends raising the CD4 threshold for Treatment U=U initiation to 500 CD4 cells or below — with priority given to people who are symptomatic or have CD4 cell counts at or below 350. As this graphic from AVAC Report 2013 illustrates, this shift in guidelines will increase the gap between the number of people eligible for ART worldwide and those currently receiving it.
The Tipping Point: Understanding a crucial milestone in the AIDS response
VMMC (VMMC) Device Evaluations
There is a range of evaluation studies underway to learn more about how non-surgical devices can be used for adult male circumcision. This map from AVAC illustrates enrolling, ongoing or recently completed VMMC (VMMC) device evaluations as of 2013.